| Dr Eric D Van Tassel, MD | |
|
5 Vanderbilt Park Dr, Asheville, NC 28803-1700 | |
| (828) 274-6000 | |
| (828) 277-6350 |
| Full Name | Dr Eric D Van Tassel |
|---|---|
| Gender | Male |
| Speciality | Internal Medicine - Cardiovascular Disease |
| Location | 5 Vanderbilt Park Dr, Asheville, North Carolina |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1093711194 | NPI | - | NPPES |
| 8984722 | Medicaid | NC |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RC0000X | Internal Medicine - Cardiovascular Disease | 32592 (North Carolina) | Primary |
| Entity Name | Mission Medical Associates Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1114150190 PECOS PAC ID: 0749326106 Enrollment ID: O20100313000054 |
News Archive
Guerbet LLC, USA - Guerbet, a pioneer in the field of contrast agents with more than 80 years of experience, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for Lipiodol (Ethiodized Oil) Injection for management of patients with known hepatocellular carcinoma (HCC).
The vote was a victory for Republican Gov. Rick Snyder, who pushed for passage, bucking the sentiments of many in his party. It is now all but certain that nearly half a million residents will gain coverage when Michigan joins the list of states opting to expand the program under the federal health law.
New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with chemically modified, single-stranded RNA-containing drugs.
Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2 trial of AN2728 and AN2898 to determine safety, tolerability and efficacy of the two compounds for the topical treatment of mild-to-moderate atopic dermatitis.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Eric D Van Tassel, MD 5 Vanderbilt Park Dr, Asheville, NC 28803-1700 Ph: (828) 274-6000 | Dr Eric D Van Tassel, MD 5 Vanderbilt Park Dr, Asheville, NC 28803-1700 Ph: (828) 274-6000 |
News Archive
Guerbet LLC, USA - Guerbet, a pioneer in the field of contrast agents with more than 80 years of experience, announced that it has been granted Orphan Drug Designation from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development (OOPD) for Lipiodol (Ethiodized Oil) Injection for management of patients with known hepatocellular carcinoma (HCC).
The vote was a victory for Republican Gov. Rick Snyder, who pushed for passage, bucking the sentiments of many in his party. It is now all but certain that nearly half a million residents will gain coverage when Michigan joins the list of states opting to expand the program under the federal health law.
New findings from two double-blind, randomized trials, RE-MEDY and RE-SONATE, show that dabigatran 150 mg twice daily reduces the risk of recurrent venous thromboembolism (VTE).
Isis Pharmaceuticals, Inc. (Nasdaq: ISIS) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that the United States Patent and Trademark Office (USPTO) has allowed an Isis patent application that further expands the scope of the "Crooke" patent estate. The newly allowed patent broadly covers methods of cleaving a target RNA via a double-stranded ribonuclease mechanism, including the RNAi mechanism, with chemically modified, single-stranded RNA-containing drugs.
Anacor Pharmaceuticals announced today that the first patient has been dosed in a Phase 2 trial of AN2728 and AN2898 to determine safety, tolerability and efficacy of the two compounds for the topical treatment of mild-to-moderate atopic dermatitis.
› Verified 5 days ago
Dr. William R Harlan Iii, M.D. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 191 Biltmore Ave, Asheville, NC 28801 Phone: 828-254-0881 Fax: 828-254-1614 | |
Dr. Nellie E. L. Fleming, MD Cardiovascular Disease Medicare: May Accept Medicare Assignments Practice Location: 509 Biltmore Ave, Asheville Hospitalist Group, Asheville, NC 28801 Phone: 828-213-4411 Fax: 828-285-9740 | |
Dr. Wade H Saunders Iii, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 5 Vanderbilt Park Dr, Asheville, NC 28803 Phone: 828-274-6000 Fax: 828-277-6350 | |
Marianne Soufas, M.D. Cardiovascular Disease Medicare: Not Enrolled in Medicare Practice Location: 68 Sweeten Creek Rd, Asheville, NC 28803 Phone: 828-274-9567 Fax: 828-255-2865 | |
Dr. Bryan J Pace, D.O. Cardiovascular Disease Medicare: Accepting Medicare Assignments Practice Location: 5 Vanderbilt Park Dr, Asheville, NC 28803 Phone: 828-274-6000 Fax: 828-274-6025 | |
Zachary Dillon Glenn, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 509 Biltmore Ave, Asheville, NC 28801 Phone: 828-213-1111 | |
Dr. Jeffrey Tyler Ramsey, DO Cardiovascular Disease Medicare: Medicare Enrolled Practice Location: 123 Hendersonville Rd, Asheville, NC 28803 Phone: 828-407-2415 Fax: 828-412-4171 |